Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Consolidated Financial Results for the Six Months Ended June 30, 2025 (Based on Japanese GAAP)
Q2 FY12/25 Financial Results Briefing Materials
Announcement regarding the decision to develop a new pipeline“H-1129”
Announcement of Launch in Thailand for Glaucoma and Ocular Hypertension Treatment“GLA-ALPHA Combination Ophthalmic Solution (Japanese product name)”
Announcement regarding the commencement of joint research with Chordia Therapeutics Inc.
Notification of Approval in Singapore for Glaucoma and Ocular Hypertension Treatment “GLA-ALPHA Combination Ophthalmic Solution”
Announcement of completion of subject dosing in global Phase III clinical trial of "K-321," a treatment for Fuchs endothelial corneal dystrophy
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)
Consolidated Financial Results for the Three Months Ended March 31, 2025 (Based on Japanese GAAP)